PURE Bioscience (OTCMKTS:PURE) CEO Henry R. Lambert sold 41,500 shares of the company’s stock in a transaction on Friday, January 12th. The stock was sold at an average price of $0.93, for a total transaction of $38,595.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Shares of PURE Bioscience (OTCMKTS:PURE) opened at $0.90 on Monday. The company has a market cap of $61.18, a PE ratio of -8.18 and a beta of -1.48. PURE Bioscience has a 1-year low of $0.83 and a 1-year high of $1.36.
PURE Bioscience (OTCMKTS:PURE) last announced its earnings results on Thursday, December 14th. The company reported ($0.04) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.02). The firm had revenue of $0.46 million during the quarter, compared to analysts’ expectations of $0.65 million. PURE Bioscience had a negative net margin of 388.83% and a negative return on equity of 210.88%. analysts expect that PURE Bioscience will post -0.08 earnings per share for the current fiscal year.
WARNING: “Henry R. Lambert Sells 41,500 Shares of PURE Bioscience (PURE) Stock” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.com-unik.info/2018/01/15/henry-r-lambert-sells-41500-shares-of-pure-bioscience-pure-stock.html.
About PURE Bioscience
PURE Bioscience, Inc is focused on developing and commercializing antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. The Company’s technology platform is based on stabilized ionic silver and its products contain silver dihydrogen citrate (SDC).
Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.